TG Therapeutics, Inc. (FRA:NKB2)

Market Cap	4.46B -0.8%
Revenue (ttm)	607.41M +81.3%
Net Income	400.60M +1,079.8%
EPS	2.49 +1,105.5%
Shares Out	n/a
PE Ratio	11.13
Forward PE	17.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	31.30
Previous Close	31.80
Day's Range	31.30 - 32.60
52-Week Range	22.47 - 36.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 6, 2026

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...

• Industry: Pharmaceutical Preparations
• Founded: 1993
• Employees: 399
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NKB2

Financial Performance

In 2025, TG Therapeutics's revenue was $616.29 million, an increase of 87.32% compared to the previous year's $329.00 million. Earnings were $447.18 million, an increase of 1812.41%.

Financial numbers in USD